BMJ metanalysis of toxicity w/ checkpoint inhibitors shows risks w/ atezolizumab (hypothyroid, N/V) , pembrolizumab (arthralgia, pneumonitis, hepatic tox), ipilimumab (skin/GI/renal), nivolumab (milder, endocrine); Nivolumab (best safety w/ lung CA) https://t.co/qzcehpLe4S